UNSPSC 51381513: Glafenine hydrochloride

This classification denotes an analgesic agent C19H17ClN2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MS23T96ZZP, chemically known as benzoic acid, 2-((7-chloro-4-quinolinyl)amino)-, 2,3-dihydroxypropyl ester, hydrochloride (1:1), but more generally known as glafenine hydrochloride, which bears US NIH Compound Identifier 3085326. European Medicines Agency schedules Glafenine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02339MIG.

Most nations, for tariff and trade purposes, schedule glafenine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, GLAFENINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(C(C1)C(=O)OCC(CO)O)NC2CCNC3C2CCC(C3)CL.CL.

UNSPSC 51381513 Glafenine hydrochloride is a Commodity code whose recent state and local posting activity shows minimal alignment with the nominal pharmaceutical ingredient. The three opportunities posted in the past six months span naloxone procurement, direct-to-manufacturer prescription program structuring, and multi-source generic pharmaceutical supply — none of which centers on glafenine hydrochloride specifically. State and local buyers soliciting under this code are pursuing pharmaceutical products and pharmacy benefit services broadly, with issuing bodies spanning county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The scope includes community health supply for emergency response (naloxone and drug deactivation systems), pharmacy benefit program innovation (direct contracting with manufacturers), and manufacturer supply agreements for generic and over-the-counter medications distributed through authorized wholesalers to state and local facilities across multiple jurisdictions.

Activity under the code concentrates in Florida, Texas, and Minnesota, with the most recent solicitation being Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. Texas HHS issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs before issuing a formal RFP. MMCAP released an RFP (S1070000015802, posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers to participating state and local facilities in Minnesota and Oregon, with awarded vendors to be notified by May 15, 2026 and contracts effective July 1, 2026. The code shows activity but no dominant theme; practitioners should verify code assignment against actual procurement scope before pursuing.